Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Descriptor ID |
D017430
|
MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 7 | 14 | 21 |
1995 | 11 | 8 | 19 |
1996 | 6 | 7 | 13 |
1997 | 5 | 9 | 14 |
1998 | 8 | 6 | 14 |
1999 | 7 | 13 | 20 |
2000 | 4 | 9 | 13 |
2001 | 2 | 11 | 13 |
2002 | 6 | 10 | 16 |
2003 | 11 | 30 | 41 |
2004 | 13 | 16 | 29 |
2005 | 11 | 16 | 27 |
2006 | 16 | 20 | 36 |
2007 | 8 | 31 | 39 |
2008 | 6 | 19 | 25 |
2009 | 11 | 13 | 24 |
2010 | 11 | 18 | 29 |
2011 | 12 | 33 | 45 |
2012 | 9 | 12 | 21 |
2013 | 9 | 17 | 26 |
2014 | 5 | 15 | 20 |
2015 | 5 | 12 | 17 |
2016 | 7 | 9 | 16 |
2017 | 3 | 15 | 18 |
2018 | 1 | 10 | 11 |
2019 | 4 | 11 | 15 |
2020 | 5 | 16 | 21 |
2021 | 3 | 12 | 15 |
2022 | 1 | 8 | 9 |
2023 | 4 | 10 | 14 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr; 211(4):518-525.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr; 211(4):526-532.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 Apr; 211(4):509-517.
-
Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024 01 23; 331(4):302-317.
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 Dec 01; 6(12):e2348692.
-
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer. Radiographics. 2023 Dec; 43(12):e230112.
-
Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort. Urol Pract. 2024 Jan; 11(1):117-122.
-
Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level =0.2 ng/mL. Clin Nucl Med. 2023 Dec 01; 48(12):1021-1027.
-
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access?to Imaging and Treatment of Metastatic Prostate Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):e628-e635.
-
ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer. Prostate. 2023 10; 83(14):1323-1331.